Issue Contents:  Sep 27, 2000

• Peptide Alliance With Baxter Puts End To Merger Talks With Cantab
• Scotia Suffers Setback As Foscan Deemed Not Approvable By FDA
• XTL Raises $44M In London IPO; Company Value Grows To $230M
• Genmab Seeks EUR240M In Dual Neuer Markt, Copenhagen IPO
• Other News To Note
• Pantheco Reports Progress With AntiSense Antibiotics
• Stem Cells From Brain Can Form Muscle Cells, Italian Study Shows
• Meristem Completes Phase I Of Plant Engineered-Derived Drug
• Oxford Glyco Seeks Added Nasdaq Listing For U.S. Deals
• EU Committee Shoots Down Italian Concerns Over GM Food
• NIH Funds Study Of NicOx Drugs For Cancer Indications
• Syn X Pharma Expands Efforts From Diagnostics To Cardiac Therapeutics
• EU Group Makes Progress In Alliance For Rare Diseases

      The above issue is also available as one PDF File